You are here: Industry Insights > lung cancer

News List

Cancer Research UK, CRT and HitGen to develop new drugs against lung cancer pharmaceutical-technology
March 02, 2017
Cancer Research UK, Cancer Research Technology (CRT) and biotech company HitGen have signed a licence agreement to develop new drugs against lung cancer.
NICE rejects MSD’s Keytruda in first-line setting pharmatimes
March 02, 2017
Patients with lung cancer are unlikely to get routine NHS access to MSD's immunotherapy Keytruda in England ...
HITGEN and Cancer Research UK’s Manchester institute enter license agreement in lung cancer HITGEN
February 28, 2017
Cancer Research UK, Cancer Research Technology (CRT) announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Novartis receives positive CHMP opinion for lung cancer combination europeanpharmaceuticalreview
February 28, 2017
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion.
EU nod for Roche’s lung cancer drug Alecensa pharmatimes
February 23, 2017
European regulators have given the go-ahead to Roche's Alecensa as a treatment for people with previously treated ALK-positive non-small cell lung cancer (NSCLC).
Chinese affordable lung cancer drug hits market english.qianlong
February 20, 2017
A generic targeted drug to treat cancer manufactured by a Chinese pharmaceutical company hit market over the weekend.
A Review of the World’s Lung Cancer Targeting Drugs en-cphi.cn
January 25, 2017
The lung cancer incidence increasingly rises and draws much attention under the environment that the haze becomes increasingly serious and the air for the survival of human kinds becomes worse and worse.
Bristol-Myers Squibb won't seek accelerated US approval of Opdivo, Yervoy combination in first-line firstwordpharma
January 22, 2017
Bristol-Myers Squibb announced that it will not pursue an accelerated regulatory pathway for the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line lung cancer in the US based on a review of current data.
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer americanpharmaceuticalreview
January 22, 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page